NASDAQ:ENGN | Cash Flow Statement | enGene Therapeutics Inc.

Complete source-backed cash-flow history.

Available history
2022-10-31 to 2026-04-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-04-30-$30.23M$200,000.00
2026-01-31-$29.75M$189,000.00-$28.9M$153,000.00-$126.3M$141.66M
2025-10-31-$37.88M$200,000.00-$24.96M$437,000.00$40.5M$1.99M
2025-07-31-$28.99M$100,000.00
2025-04-30-$25.82M$100,000.00
2025-01-31-$24.62M$102,000.00-$25.7M$299,000.00-$84.96M$1,000.00
2024-10-31-$15.3M$100,000.00-$19.57M$238,000.00-$125.27M$60.16M
2024-07-31-$14.15M$100,000.00
2024-04-30-$14.98M$100,000.00
2024-01-31-$10.71M$80,000.00-$7.37M$506,000.00-$506,000.00$12M
2023-10-31-$82.5M$74,000.00-$6.78M$138,000.00-$138,000.00$50.84M
2023-07-31-$4.72M$43,000.00
2023-04-30-$5.28M$37,000.00
2023-01-31-$7.42M$46,000.00-$6.22M$13,000.00-$13,000.00-$10,000.00

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-10-31-$117.3M$500,000.00-$99.24M$1.49M-$25.14M$1.52M
2024-10-31-$55.14M$300,000.00-$48.28M$925,000.00-$125.95M$265.72M
2023-10-31-$99.92M$200,000.00-$24.74M$318,000.00-$318,000.00$0.00$86.15M
2022-10-31-$24.46M$200,000.00-$17.59M$153,000.00-$153,000.00$27.97M